2025 TOPA 10th Annual Conference


Date: Aug 9, 2025 01:00 AM

Fee

$0.00

CE Hours

6.00

CE Units

0.600

Registration closes on Sep 09, 2025 01:00 AM

Activity Type

Knowledge

Target Audience(s)

Pharmacists

Accreditation(s)

Accreditation Council for Pharmacy Education
University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

 

 

Registration start from
08/09/2025  

Colorectal and upper GI cancers have traditionally been treated with fluoropyrimidine based agents in various combinations and settings. Novel therapies have upset this balance, now being utilized either on their own or in combination with chemotherapy regimens. Given this change and need to understand when these new agents should be utilized, pharmacists should understand how these agents came to be. Additionally, these agents often have different mechanisms and adverse effects from traditional chemotherapies, so pharmacists need to understand how to manage these different side effects. The purpose of this knowledge-based activity is to analyze trial data for novel therapies in GI malignancies and where these agents fall in the treatment paradigm.

Objectives

  • Compare trial data for novel medications and expanded use in gastrointestinal malignancies.
  • Define adverse effects commonly associated with new agents.
  • Review guidelines for upper GI and colorectal cancers and how data is incorporated into recommendations.
  • Cite evidence-based recommendations to patient cases.

Speaker(s)/Author(s)

Dennis Marjoncu, PharmD, BCOP
Clinical Pharmacy Specialist- Hematopoietic Cell Transplantation, Methodist University Hospital

Activity Number

0064-9999-25-055-L01-P
Date: 08/09/25
Time: 01:00 AM - 01:00 AM

CE Hours

1.00
Registration start from
08/09/2025  

Registration start from
08/09/2025  

Endocrine refractory hormone-positive metastatic breast cancer historically had poor outcomes with limited treatment options available. Within the last few years, several targeted agents have been approved along with expanded indications to other medications. With the numerous medications now in this space, it’s important that pharmacists are aware of the data and side effects of these medications to provide the best patient care.

Objectives

  • Explain trial data for novel medications and expanded use in metastatic hormone-positive endocrine refractory breast cancer.
  • Discuss adverse effects commonly associated with these medications.
  • Review guidelines for breast cancer and how data is incorporated into recommendations.
  • Select evidence-based recommendations for patient cases.

Speaker(s)/Author(s)

Kori Holman-Daniels

Activity Number

0064-9999-25-057-L01-P
Date: 08/09/25
Time: 01:00 AM - 01:00 AM

CE Hours

1.00
Registration start from
08/09/2025  

Registration start from
08/09/2025  

Acute myeloid leukemia treatment varies based on several factors including cytogenetic risk factors, patient performance status or comorbidities, and prescriber insight. Venetoclax received its indication for AML based on results from the VIALE-A trial, and the updates published for long-term follow-up will help guide clinician decision due to more available information on safety profile, new data on MRD status, and overall survival impact. Current FDA-approved regimens for venetoclax include combinations with hypomethylating agents or low-dose cytarabine for this population. Our field continues to see evolution of venetoclax use as exhibited in the most recent 2025 NCCN guideline updates in the relapsed/refractory space. In the field of CLL, venetoclax combinations continue to be used in various settings, notably in the first fixed-duration first-line regimen, as well as in novel therapeutic combinations, each with their own supportive care, side effects, and monitoring.

Objectives

  • Explain the available long-term follow-up data from the VIALE-A trial.
  • Compare trial data for novel venetoclax combinations in AML and CLL.
  • Describe real-world use of novel venetoclax combinations in AML patients.
  • Identify information from trial data to incorporate into a CLL patient case.

Speaker(s)/Author(s)

Dennis Marjoncu, PharmD, BCOP
Clinical Pharmacy Specialist- Hematopoietic Cell Transplantation, Methodist University Hospital

Lexi Taylor

Activity Number

0064-9999-25-058-L01-P
Date: 08/09/25
Time: 01:00 AM - 01:00 AM

CE Hours

1.00
Registration start from
08/09/2025  

Registration start from
08/09/2025  

Expanded access programs exist to assist patients and providers in accessing treatment for patients when they have exhausted all recommended therapies.However, providers may not be aware of how to obtain expanded access for patients.Being aware of the intention and steps involved in the process will help facilitate patient care in this setting.

Objectives

  • Explain what expanded access entails.
  • Describe the responsibilities of physicians and sponsors.
  • Identify the key steps in submitting an EA request.

Speaker(s)/Author(s)

Glenn Roma, PharmD, PhD
Investigational Drug Service Pharmacist, Baptist Cancer Center

Activity Number

0064-9999-25-059-L01-P
Date: 08/09/25
Time: 01:00 AM - 01:00 AM

CE Hours

0.50
Registration start from
08/09/2025  

Registration start from
08/09/2025  

Revumenib is the first FDA-approved menin inhibitor and is approved for the treatment of relapsed or refractory (R/R) acute leukemia with rearrangements in the histone-lysine N-methyltransferase 2A gene (KMT2Ar) (J Clin Oncol. 2025;43(1):75-84). KMT2Ar is present in ~5-10% of patients with acute myeloid leukemia (AML). This subset of AML is typically associated with decreased sensitivity to chemotherapy and shorter duration of remission with currently available treatment options. Revumenib is the first available targeted therapy for patients with relapsed or refractory KMT2Ar AML. Clinicians who care for patients with relapsed/refractory AML should be aware of this additional treatment option available to patients.
 
This continuing education presentation will be a useful education tool to increase the participants’ knowledge base by reviewing and discussing the clinical data regarding the safety and efficacy of revumenib in the treatment of KMT2Ar relapsed/refractory acute leukemia. The National Comprehensive Cancer Network (NCCN) AML guidelines will be reviewed as well as articles from peer-reviewed journals, including the landmark trial demonstrating the efficacy and safety of revumenib in this patient population.
 
The goal of this continuing education is for attendees to enhance their knowledge regarding the role of revumenib in the management of R/R KMT2Ar AML and to recognize the common and potentially serious adverse effects and appropriate monitoring and management strategies.

Objectives

  • Describe the pharmacology and indications for revumenib, a menin inhibitor, in the treatment of acute myeloid leukemia.
  • Review and interpret the clinical data regarding the safety and efficacy of revumenib in patients with relapsed or refractory acute leukemia.

Speaker(s)/Author(s)

Callee Brook

Activity Number

0064-9999-25-062-L01-P
Date: 08/09/25
Time: 01:00 AM - 01:00 AM

CE Hours

0.50
Registration start from
08/09/2025  

Registration start from
08/09/2025  

VBC has the ability to reshape healthcare, taking us from volume-focused to value-focused.Collaboration between healthcare teams and roles can improve health outcomes and the patient experience while reducing unnecessary utilization and healthcare spend.By reducing system fragmentation and incorporating multidisciplinary teams in the care of our patients, we can improve care quality, keep patients engaged in their care, and reduce costs.The purpose of this activity is to review current VBC models and identify how pharmacists can play a role in achieving these VBC goals.

Objectives

  • Define value-based care (VBC).
  • Explain how “value” is determined.
  • Identify the key benefits of VBC for patients, providers, and healthcare system.
  • Discuss the importance of data in the VBC space.
  • Describe how performance is evaluated and improved.

Speaker(s)/Author(s)

Leah Owens

Activity Number

0064-9999-25-063-L01-P
Date: 08/09/25
Time: 01:00 AM - 01:00 AM

CE Hours

0.50
Registration start from
08/09/2025  

Registration start from
08/09/2025  

This activity provides knowledge-based learning on gynecologic oncology treatment paradigms to increase pharmacists’ confidence and understanding with how to best monitor and manage these patients. This will allow individuals to provide the top quality of standard of care regimens while staying up to date on treatment advancements and improving patient outcomes in this population.

Objectives

  • Identify recent clinical trials investigating the efficacy and safety of recently approved regimens in ovarian, cervical, endometrial and uterine cancer.
  • Identify the place in therapy for approved treatment regimens.
  • Describe treatment regimens based on patient-specific and disease-related factors.

Speaker(s)/Author(s)

Sara Nezirevic

Activity Number

0064-9999-25-064-L01-P
Date: 08/09/25
Time: 01:00 AM - 01:00 AM

CE Hours

1.00
Registration start from
08/09/2025  

Registration start from
08/09/2025  

Bispecific T-cell engager antibodies represent a promising advancement offering targeted therapy for patients. However, the transition to outpatient treatment presents unique challenges including ensuring proper patient monitoring, coordinating multidisciplinary care, and managing potential side effects in the outpatient setting.

This presentation will address operational aspects of implementing bispecific T-cell engager therapies in the outpatient setting. By providing targeted education, standardizing outpatient administration protocols, and improving patient support pharmacists can help to enhance patient care, mitigate risks, and integrate bispecific T-cell engager therapies effectively into the outpatient care space.

Objectives

  • Identify operational challenges in initiating outpatient bispecific T-cell engager therapies, including patient selection and care coordination.
  • Describe workflow for safely implementing bispecific T-cell engager therapies in the outpatient setting.
  • Recognize guidelines for managing bispecific T-cell engager toxicities in both outpatient and inpatient settings.
  • Review educational materials for staff, patients, and caregivers on bispecific T-cell engager therapies.

Speaker(s)/Author(s)

Rhiannon Dorris

Activity Number

0064-9999-25-065-L01-P
Date: 08/09/25
Time: 01:00 AM - 01:00 AM

CE Hours

0.50
Registration start from
08/09/2025